**Date and Time:** 25th September 2012; 10.30 – 16.30hrs

**Minutes:**

<table>
<thead>
<tr>
<th>Guideline Development Group Meeting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Place: Donald Hunter Room, Royal College of Physicians, London</td>
</tr>
</tbody>
</table>

**Present:**

Philip Conaghan (Chair)
Mark Porcheret (MP)
Elspeth Wise (EW)
Ian Bernstein (IB)
Fraser Birrell (FB)
Michael Doherty (MD)
Peter Kay (PK)
Rob Middleton (RM)
Brian Lucas (BL)
Krycia Dziedzic (KD)
Weiya Zhang (WZ)
Erika Baker (EB)
Tony Whiting (TW)
Jo Cumming (JC)

Vanessa Delgado Nunes, Guideline Lead and Senior Research Fellow (VDN)
Emmert Roberts, Research Fellow (ER)
Sara Buckner, Research Fellow (SB)
Margaret Constanti, Health Economist (MC)
Sue Latchem, Guideline Lead and Operations Director (SL)
Paul Miller, Information Scientist (PM)

Ben Doak, Guidelines Commissioning Manager, NICE

<table>
<thead>
<tr>
<th>Co-opted experts</th>
</tr>
</thead>
<tbody>
<tr>
<td>None for this meeting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Apologies:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Frearson</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Observers:</th>
</tr>
</thead>
<tbody>
<tr>
<td>None for this meeting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Declarations of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC</td>
</tr>
</tbody>
</table>
Declared personal pecuniary interests:

Attended an advisory board on new anti-nerve growth factor therapy for OA (Fulranumab) developed by Janssen-Cillag. It is still in Phase III trial phase and is not related to the scope of this guideline. Funding will go into department.

Attended an advisory board on new anti-nerve growth factor therapy for OA (Tanezumab) and is developed by Pfizer. It is still in Phase III trial phase and is not related to the scope of this guideline. Funding will go into department.

Declared a personal non-pecuniary interest:
Speaker at RCP London on “What's new in OA?”, upon invitation from the RCP.

MP
Declared a personal non-pecuniary interest:
MP will be presenting at RCGP annual conference 5th Oct 2012-short update for GPs on OA, covering diagnosis and treatment and will present data from two studies: adverse events from paracetamol in patients with knee OA and benefit of exercise in patients with knee OA.

BW
Declared a personal pecuniary interest:
Recently attended (Sept 13th-14th) the Royal College of Nursing's Society of Orthopaedic and Trauma Nursing annual conference in Manchester. As Chair of the Society the RCN paid for his travel (second class rail ticket), conference fee and 2 nights hotel accommodation.

EW
Declared personal pecuniary interests:
Servier (make protelos - an osteoporosis drug which had a recent study showing that it may be effective in OA) are arranging to do an osteoporosis and an osteoarthritis audit in a couple of surgeries to see what the cross over is. EW and her surgery are involved and are not getting paid for this. EW is advising Servier as to what they may want to search for in the audit.
EW attended a drug advisory board meeting for a drug/device which is not let licensed made by Pro Bono Bio. The meeting was chaired by Phil Conaghan. The honorarium is going to her surgery.
EW wrote an article about the use of opioids in the management of back pain for a Pulse supplement. EW will be paid for this, but is unsure about the amount at this stage.

Declared a personal non pecuniary interest:
EW wrote some comments on two reports about the EULAR meeting for guidelines in practice. They were mainly about rheumatoid and all experimental so not OA related.

There were no changes in any of the other GDG members’ or NCGC staff’s DOIs since the last meeting.

No actions were taken following these declarations and none of the GDG members withdrew as none of the declarations conflicted with clinical areas to be discussed during the GDG meeting.

1. Philip Conaghan welcomed the group to the fifth meeting of this GDG. Philip Conaghan asked the GDG for any new DOIs since GDG meeting 1.
2. Emmert Roberts presented the clinical and cost effectiveness evidence related to the use of paracetamol in the management of OA (trial data).

3. Sara Buckner presented the evidence related to the adverse events of paracetamol in the general population (observational data).

4. Philip Conaghan, Vanessa Delgado Nunes and Sue Latchem facilitated discussion and decision making with the GDG in terms of the evidence for the efficacy and safety profile of paracetamol.

5. Emmert Roberts presented the clinical and cost effectiveness evidence related to the use of etoricoxib 30mg in the management of OA.

6. Philip Conaghan, Vanessa Delgado Nunes and Sue Latchem facilitated discussion and decision making with the GDG in terms of the evidence for the efficacy and safety profile of etoricoxib 30mg.

7. Vanessa Delgado Nunes presented and agreed with the GDG the evidence review protocols on the diagnosis of OA and fixed dose NSAIDs+ GPA for the November GDG meeting.

8. Margaret Constanti updated the GDG with the progress on the health economics modelling work for the guideline update.

9. Philip Conaghan asked the GDG whether there were any items under AOB and closed the meeting at 16.50hrs.

**Date, time and venue of the next meeting**

7th November 2012, 10:30 – 16:30hrs.